Combinatorial drug therapy for cancer in the post-genomic era.
about
Glycogen synthase kinase-3β is a pivotal mediator of cancer invasion and resistance to therapyOvercoming Barriers in Oncolytic Virotherapy with HDAC Inhibitors and Immune Checkpoint BlockadeMaximizing the Therapeutic Potential of HSP90 InhibitorsEvolutionary determinants of cancerTargeting melanoma by small molecules: challenges aheadWhat a tangled web we weave: emerging resistance mechanisms to inhibition of the phosphoinositide 3-kinase pathwayFunctional genomics lead to new therapies in follicular lymphomaPersonalized cancer medicine: molecular diagnostics, predictive biomarkers, and drug resistanceQuantitative phenotypic and pathway profiling guides rational drug combination strategiesPreclinical mouse cancer models: a maze of opportunities and challenges.Serial low doses of sorafenib enhance therapeutic efficacy of adoptive T cell therapy in a murine model by improving tumor microenvironmentEpigenetic polypharmacology: from combination therapy to multitargeted drugsApproaches to modernize the combination drug development paradigmEngineered Nanoparticles Against MDR in Cancer: The State of the Art and its Prospective.Biomolecular Network-Based Synergistic Drug Combination DiscoveryDual small-molecule targeting of procaspase-3 dramatically enhances zymogen activation and anticancer activityCombination of a proteomics approach and reengineering of meso scale network models for prediction of mode-of-action for tyrosine kinase inhibitorsTarget inhibition networks: predicting selective combinations of druggable targets to block cancer survival pathwaysDiscovering anti-platelet drug combinations with an integrated model of activator-inhibitor relationships, activator-activator synergies and inhibitor-inhibitor synergiesProgressive Hemorrhage and Myotoxicity Induced by Echis carinatus Venom in Murine Model: Neutralization by Inhibitor Cocktail of N,N,N',N'-Tetrakis (2-Pyridylmethyl) Ethane-1,2-Diamine and SilymarinSelective Targeting of CTNBB1-, KRAS- or MYC-Driven Cell Growth by Combinations of Existing DrugsDiscovery of Drug Synergies in Gastric Cancer Cells Predicted by Logical ModelingTetra-O-Methyl Nordihydroguaiaretic Acid Broadly Suppresses Cancer Metabolism and Synergistically Induces Strong Anticancer Activity in Combination with Etoposide, Rapamycin and UCN-01Distinctive Behaviors of Druggable Proteins in Cellular NetworksIdentifying enriched drug fragments as possible candidates for metabolic engineeringMechanistic Nanotherapeutic Approach Based on siRNA-Mediated DJ-1 Protein Suppression for Platinum-Resistant Ovarian CancerNetwork modeling of TGFβ signaling in hepatocellular carcinoma epithelial-to-mesenchymal transition reveals joint sonic hedgehog and Wnt pathway activationSelective intracellular vaporisation of antibody-conjugated phase-change nano-droplets in vitroPolymeric Nanostructures for Imaging and TherapyHarnessing Connectivity in a Large-Scale Small-Molecule Sensitivity Dataset.High-throughput combinatorial screening identifies drugs that cooperate with ibrutinib to kill activated B-cell-like diffuse large B-cell lymphoma cells.A data-driven approach for evaluating multi-modal therapy in traumatic brain injury.Inferring the perturbed microRNA regulatory networks from gene expression data using a network propagation based method.Polypharmacology in Precision Oncology: Current Applications and Future ProspectsCharacteristics of drug combination therapy in oncology by analyzing clinical trial data on ClinicalTrials.gov.Identifying kinase dependency in cancer cells by integrating high-throughput drug screening and kinase inhibition dataMutation based treatment recommendations from next generation sequencing data: a comparison of web toolsMinimizing bias in target selection by exploiting multidisciplinary Big Data and the protein interactome.Regulation of voltage-gated potassium channels attenuates resistance of side-population cells to gefitinib in the human lung cancer cell line NCI-H460Update: the status of clinical trials with kinase inhibitors in thyroid cancer
P2860
Q26739711-575B5976-F53F-440D-BFF2-71DDD9FE050AQ26769977-353C6F4D-54C2-49F4-B085-5B3AAD6C5184Q26798318-A943F709-F34A-4C57-AD2B-A787F6E722D5Q26801710-A1FFAAA5-086C-42EC-AE25-AA5D2FFBAE04Q26824642-DB027CB7-9D3D-479C-BA5A-EF77FB45AE6DQ26825780-8C82E3AD-EF76-4AEE-A10D-2D334070B54FQ26852415-BD47F6E5-1C07-48D8-8F71-DF9163DE9FADQ26866517-E2997E71-CDD6-4C43-9A9B-C6B9DD88FBE5Q27021150-9B344389-3851-4D3C-ADD4-23E094732A50Q27322080-1DAE4858-6117-44AF-BD1F-232043D6F0EDQ27335748-A779A676-81C8-428C-9EA1-2B13DE5BB67FQ28067666-126A176A-BFFB-4B63-8AB8-1D410A58A861Q28072074-964A7BBC-8135-42E9-A695-037CFC384FD5Q28073956-414D3EB6-9E39-4CCE-AB05-66097A148DCBQ28077880-A94A4380-C798-46C2-B88C-CE1170BF5D74Q28304985-399982F2-3FC3-4FC9-9E66-7F0661712FAEQ28484913-41CA07FA-E4E4-44B4-B98A-113523D8AE5FQ28533401-515507B1-C54D-41E4-A37A-9E0BF6E6A414Q28546587-239B39B6-196F-4007-AF10-D34EA50B7BFDQ28547272-DB0265AF-ED17-43BB-AA0E-E61080E1FF5FQ28547522-0A220990-99A4-43D1-A37F-64A1290E5D88Q28547862-AD314E64-2AAC-4406-98A7-7AE04C109539Q28550253-B5F414E2-55DF-4C3A-A815-367D0151EEC6Q28551715-E7D59958-6A4B-4B26-BB54-1CA6C746B82AQ28830613-55B67333-274C-46B6-8821-6548979B1454Q29247912-A7130A52-13E3-4B6E-A235-49F57301851BQ30359446-1D243058-8510-42B1-9B1C-8C2568DA686CQ30360403-5077967D-6429-449F-8D86-5FB7CCB2061CQ30372383-04C49FB8-0263-4FFA-A530-3DED0C700AD9Q30384542-A41E1C6C-D799-43BB-BC87-75BE5794DF17Q30433183-748D9488-E8BA-4D91-B59A-A62AD84EE878Q30838850-CD1A30F8-D98A-42D0-A15E-35E4FC2D26FEQ30839150-D735D040-B8B7-413F-A3CD-91B77CE896F9Q30846907-6DBD52EE-4C18-4581-A08C-45C1EA915468Q30884583-F2A04977-9F24-4F81-996C-AF0E2E0BBF89Q30982375-B59CDF5B-7BFA-4FA2-A09C-D9A09C463566Q31058925-FB14B088-3C99-46A1-8EA3-011F6ECA1A6CQ31125908-F1A5A420-FDDC-492C-9298-0C0539058848Q32181933-6D50562C-B154-427E-8D2F-643B3C7C94EDQ33570056-5B40DFCB-6518-4E68-A51D-990738DC6FF2
P2860
Combinatorial drug therapy for cancer in the post-genomic era.
description
2012 nî lūn-bûn
@nan
2012 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Combinatorial drug therapy for cancer in the post-genomic era.
@ast
Combinatorial drug therapy for cancer in the post-genomic era.
@en
Combinatorial drug therapy for cancer in the post-genomic era.
@nl
type
label
Combinatorial drug therapy for cancer in the post-genomic era.
@ast
Combinatorial drug therapy for cancer in the post-genomic era.
@en
Combinatorial drug therapy for cancer in the post-genomic era.
@nl
prefLabel
Combinatorial drug therapy for cancer in the post-genomic era.
@ast
Combinatorial drug therapy for cancer in the post-genomic era.
@en
Combinatorial drug therapy for cancer in the post-genomic era.
@nl
P50
P356
P1433
P1476
Combinatorial drug therapy for cancer in the post-genomic era.
@en
P2888
P304
P356
10.1038/NBT.2284
P577
2012-07-10T00:00:00Z
P5875
P6179
1012514299